Posted on 10/19/17
Johnson & Johnson To Acquire Surgical Process Institute
Johnson & Johnson's (NYSE:JNJ) German device unit Johnson & Johnson GmbH inks an agreement to acquire German software firm Surgical Process Institute (SPI), a specialist in . . .
Posted on 10/19/17
Johnson & Johnson: One-Time Bumps
Before the open, Johnson & Johnson (JNJ) reported Q3 results that at first glance appear amazing. Investors though need to consider the one-time benefits before getting . . .
Posted on 10/19/17
Johnson & Johnson At All-Time Highs: Time To Sell Or To Buy?
Johnson & Johnson's (JNJ) third quarter results showcase why the company remains one of the best dividend growth stocks: Consistent earnings growth, attractive shareholder returns, a . . .
Posted on 10/19/17
Teva Bulls Are Too Early: Debt Downgrade On The Way
If a stock is under pressure, I’m interested. I never jump as quickly as into the story as some other authors here, but I’ll happily purchase . . .
Posted on 10/19/17
J&J: Unattractive
Why Q3 was a downerJohnson & Johnson (JNJ), a Dow 30 (DIA) stock and one of only two remaining AAA-rated credits among US-based corporations, reported earnings . . .
Posted on 10/19/17
What's Powering Johnson & Johnson's Impressive Quarterly Earnings?
Johnson & Johnson (NYSE:JNJ) surprised investors with better-than-hoped-for top-line and bottom-line performance in the third quarter, and that news sent shares soaring on Tuesday. The company's . . .
Posted on 10/18/17
Johnson & Johnson: The Unsinkable
I had a quick exchange about Johnson & Johnson (NYSE:JNJ) with a few investors who pointed out on Tuesday that it appeared evident that the bears . . .
Posted on 10/18/17
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
Ziopharm Oncology, Inc. (NASDAQ:ZIOP) and Celldex Therapeutics, Inc. (NASDAQ:CLDX)are both clinical-stage biotechs that could make you rich, but they'll need to carry at least one of . . .
Posted on 10/18/17
Teva: The Very Long Bull Case
The Sky is Falling The Sky is Falling When things are going well and prices are high, investors rush to buy, forgetting all prudence. Then, when . . .
Posted on 10/18/17
Johnson & Johnson Jumps on Pharma Strength
Johnson & Johnson (NYSE:JNJ) has been a behemoth in the U.S. healthcare space for decades. Yet as a mature company, J&J faces the inevitable challenge of . . .
Posted on 10/18/17
Johnson & Johnson Q3 2017 Earnings Conference Call Transcript (JNJ)
Johnson & Johnson (NYSE:JNJ) IMAGE SOURCE: THE MOTLEY FOOL.Q3 2017 Earnings Conference CallOctober 17, 2017, 8:30 a.m. ETContents: Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood morning, and . . .
Posted on 10/18/17
Optinose Closes IPO
YARDLEY, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated . . .
Posted on 10/18/17
Aevi Genomic Medicine Completes $28 Million Private Placement
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) today announced the completion of a previously announced private placement of 22.2 million shares of its common stock with warrants to . . .
Posted on 10/18/17
RenovaCare Closes Registered Direct Offering and Concurrent Private Placement
NEW YORK & PITTSBURGH & BERLIN--(BUSINESS WIRE)--RenovaCare, Inc., (OTCQB:RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto . . .
Posted on 10/18/17
Johnson & Johnson Gets Court Reversal of Verdict Over Talc Cancer Risks
Johnson & Johnson (NYSE:JNJ) today won a reversal of a $72M verdict that had favored the family of a woman whose death from ovarian cancer they . . .
Posted on 10/17/17
OncLive Adds George Washington Cancer Center to its Strategic Alliance Partnership Program
CRANBURY, N.J.--(BUSINESS WIRE)--OncLive®, a leading digital provider of resources and information for oncology professionals announces the expansion of its Strategic Alliance Partnership (SAP) program with the . . .
Posted on 10/17/17
Understanding Johnson & Johnson's Spectacular Q3 Performance
Johnson & Johnson (JNJ) is one of the most stable publicly-traded businesses. The company is one of only two stocks to carry the coveted AAA credit . . .
Posted on 10/17/17
Teva's Ongoing Complications: Psychology And Generic Drugs
BackgroundTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company that focuses primarily on production of generic drugs. The company’s global dominance is clear as . . .
Posted on 10/17/17
Merck's Risk/Reward Is Compelling
In spite of the share price going up more than 30% since early 2016 after disappointing results for Bristol-Myers Squibb (NYSE:BMY) in lung cancer in the . . .
Posted on 10/17/17
Take Profits On Johnson & Johnson
I've discussed Johnson & Johnson's (NYSE:JNJ) various businesses from a qualitative and quantitative prospective, and it’s clear that I like the company’s long-term strategy and its . . .
Posted on 10/17/17
3 Questions You Need to Ask Ahead of Johnson & Johnson's Third-Quarter Report
Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is what you might call a staple holding in many investors' portfolios. Its superior 2.5% dividend yield and 55-year streak . . .
Posted on 10/16/17
Catalent Prices Private Offering
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that . . .
Posted on 10/16/17
Teva Rushes To Match 30% Discounts For Generic Copaxone
The major question surrounding Teva (TEVA) is how much Mylan's (MYL) generic Copaxone will impact Copaxone sales. The answer to that question began to materialize after . . .
Posted on 10/16/17
Better Buy: AbbVie Inc. vs. Merck
Leader and laggard.That's what you have with AbbVie (NYSE:ABBV) and Merck (NYSE:MRK) stocks, at least so far in 2017. AbbVie is enjoying one of its best . . .
Posted on 10/16/17
Pfizer Says It's Pondering a Big Sale
In this Market Foolery podcast, and with the big news coming out of healthcare, host Chris Hill calls upon the expert insight of Industry Focus: Healthcare . . .

